Coronavirus Has Rocked World Markets, But Are Plague Stocks A Buy?

Hilary Kramer

Hilary Kramer is an investment analyst and portfolio manager with 30 years of experience on Wall Street.

Massive disease outbreaks have changed the course of history and spawned huge Hollywood movies, but the global economy has bounced back every time.

For long-term investors, there’s no need to track the viral scenarios. All we really need to remember is that people will always get sick and medicine will always adapt to contain and treat new diseases.

It all is part of the long cycle of innovation and progress. And the next outbreak will strike somewhere else. 

But in the short term, of course, that’s not really comforting. That’s why whenever people start getting sick, market reporters always ask me to weigh the market impacts. 

The most recent interview was with Reuters. Click this link to watch it. Naturally, it revolved around the coronavirus epidemic in China that already has killed hundreds of people and quarantined millions.

That was Jan. 27. Since then, things have gotten worse, with the virus showing up in Europe while Delta Air Lines Inc. (NYSE:DAL) and American Airlines Group Inc. (NASDAQ:AAL) cancel all flights from China.

This is not my first outbreak. When I saw the headlines start, I knew exactly how this would play out on Wall Street. 

And if history plays out like it has every time before, the “plague stocks” rallying now will ultimately perform well for shareholders… but only if you take a long view and maintain diversified exposure.

Think Like a Venture Capitalist

I’ve talked a lot about the venture capital mindset lately as my new IPO service ramps up. In essence, the big fortunes that built Silicon Valley incubated for years.

Even the smartest venture capitalists know that 30-40 percent of their best ideas will ultimately fail. That’s all right. The rest will do well enough for the portfolio as a whole to double in six years.

This math revolves around statistics derived from tracking multiple positions across long periods. Otherwise, you’re really just betting on horses. The more you know about horses, the more you’ll win, but you’ll still lose a lot of the time.

Every viral outbreak is an emergent situation. We don’t know today who will cure the disease and a lot of people have strong incentives to try. One horse will cross the finish line first.

Financial reporters will ask me to name the horses and pick a favorite. As it turns out, the correct answer is simply to split your stake across all the contenders. That way, you’ll always pick the winner.

Think back to the Ebola outbreak of 2014. A handful of stocks soared once investors realized how important a cure would be. 

Sarepta Therapeutics Inc. (NASDAQ:SRPT) has been a long-term winner, soaring a healthy 530 percent since the first U.S. Ebola cases were reported. Ironically, the company’s experimental cure went nowhere, forcing other programs to fill the gap.

Drug developers with a more intense focus on Ebola did much, much worse. After surging in 2014, Arbutus Biopharma Corp. (NASDAQ:ABUS), BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) and NewLink Genetics Corp. (NASDAQ:NLNK) collectively have handed investors who bought the rally an 87 percent loss.

People talked a lot about Versar Inc. back in 2014 as well. That stock no longer exists.

If you were looking to invest in an Ebola cure six years ago, you had an 80 percent chance of picking the wrong horse. But SRPT did well enough to cushion its pain, turning a staggering loss into a 26 percent net win.

And smart investors work even harder to balance their risk while remaining open to the rewards. None of those five companies ever cured Ebola. If you can’t cure a disease, you need to find other ways to protect people.

Both Alpha Pro Tech Ltd. (NYSE:APT) and Lakeland Industries Inc. (NASDAQ:LAKE) also soared in that outbreak. They’re soaring now.

They make hazmat suits and other decontamination equipment. No matter what the disease is, they’re essential. 

Investors who added these two stocks to an Ebola portfolio ended up earning 48 percent in six years. Not bad at all… until you see the S&P 500 with its 64 percent return over the same period.

Betting on disaster only pays off big when the rest of the world suffers. I’d rather incorporate disaster stocks into a wider strategy, using them as a hedge while enjoying the good times while they last.

That’s why I stay focused on the long view. My GameChangers stocks were in place before the outbreak and will pay out after Wall Street forgets about the coronavirus, just like it forgot about Ebola, Zika or SARS. 

My goal there isn’t to find the best disaster stock and squeeze a few extra points out of an otherwise miserable outcome. I’m here to find winners.

Join Me for the Orlando MoneyShow, February 6-8, 2020, at the Omni Orlando Resort at ChampionsGate. I will be speaking Friday, Feb. 7, 3:00 p.m. about The Stealth Value Investor: Ten Amazing Dividend Yield Plays Flying Under the Radar. On Saturday, Feb. 8, I will talk at 5:15 p.m. about Identifying the Real Future GameChanger Stocks: Ten Companies Positioned to Double – Even if the Bears Take Over Wall Street. Other investment experts who will be speaking include retirement and estate planning specialist Bob Carlson, income and options expert Bryan Perry and world-traveling, free-market economist Mark Skousen, who leads the Forecasts & Strategies newsletter. Register by clicking here or call 1-800-970-4355 and mention my priority code of 049252.

Exclusive  What’s Past is Prologue for Markets in 2018

Like This Article?
Now Get Mark's FREE Special Report:
3 Dividend Plays with Sky-High Returns

This newly-released report by a top-20 living economist details three investments that are your best bets for income and appreciation for the rest of the year and beyond.

Get Access to the Report, 100% FREE


img
previous article

Investment expert Hilary Kramer discusses how and why cash is king in the cannabis sector of the stock market.

PREMIUM SERVICES FOR INVESTORS

Dr. Mark Skousen

Named one of the "Top 20 Living Economists," Dr. Skousen is a professional economist, investment expert, university professor, and author of more than 25 books.

Product Details

LEARN MORE HERE

Bryan Perry

A former Wall Street financial advisor with three decades' experience, Bryan Perry focuses his efforts on high-yield income investing and quick-hitting options plays.

Product Details

LEARN MORE HERE

Jim Woods

Jim Woods has over 20 years of experience in the markets from working as a stockbroker,
financial journalist, and money manager. As well as a book author and regular contributor to
numerous investment websites, Jim is the editor of:

Product Details

LEARN MORE HERE

Bob Carlson

Bob Carlson provides independent, objective research covering all the financial issues of retirement and retirement planning. In addition, Bob serves as Chairman of the Board of Trustees of the Fairfax County (VA) Employees’ Retirement System, which has over $2.8 billion in assets.

Product Details

LEARN MORE HERE

Hilary Kramer

Hilary Kramer is an investment analyst and portfolio manager with 30 years of experience on Wall Street. Since 2010, Hilary's financial publications have provided stock analysis and investment advice to her subscribers:

Product Details

LEARN MORE HERE

Jon Johnson

Jon Johnson's philosophy in investing and trading is to take what the market gives you regardless if that is to the upside or downside. For the past 21 years, Jon has helped thousands of clients gain success in the financial markets through his newsletters and education services:

Product Details

LEARN MORE HERE

DividendInvestor.com

Used by financial advisors and individual investors all over the world, DividendInvestor.com is the premier provider and one-stop shop for dividend information and research.

Product Details

Popular tools include our proprietary Dividend Calendar, Dividend Calculator, Dividend Score Card, and many more.

LEARN MORE HERE